Itero Biopharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
The biosimilars business isn't necessarily a logical niche for a small start-up company. The industry's many attendant challenges-clinical, manufacturing, and regulatory-are more the domain of the established generics companies, big biotechs, and more recently Big Pharmas, which have the capital and infrastructure to handle them. Try telling that to Itero Biopharmaceuticals, which plans to develop follow-on therapeutic proteins and antibodies en route to creating its own biologics pipeline. In order to compete in this multibillion-dollar market, Itero intends to forge and leverage strategic partnerships in far-flung corners of the world.